Dutch start-up VectorY Therapeutics has been given the green light by the FDA for a phase 1/2 trial of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis (ALS) cases. VTx ...
Based Detection, Linguistic Biomarkers, Machine Learning, Explainable AI, Cognitive Decline Monitoring Share and Cite: de Filippis, R. and Al Foysal, A. (2025) Early Alzheimer’s Disease Detection from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback